A patent review of CHK1 inhibitors (2019-present)
文献类型：期刊论文
| 作者 | Liu, Tao7; Su, Mingbo6; Wang, Yuxuan4,5; Gao, Anhui6; Jiang, Kailong3; Xu, Lei3; Li, Jia1,2,3,6 |
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2025-09-02 |
| 卷号 | 35期号:9页码:915-931 |
| 关键词 | CHK1 DDR CHK1 inhibitor cancer therapy patent combination predictive biomarker |
| ISSN号 | 1354-3776 |
| DOI | 10.1080/13543776.2025.2545792 |
| 通讯作者 | Liu, Tao(Lt601@zju.edu.cn) ; Li, Jia(jli@simm.ac.cn) |
| 英文摘要 | IntroductionCheckpoint kinase 1 (CHK1), a serine/threonine kinase, plays an important role in the DNA damage response (DDR), such as cell cycle checkpoints, DNA repair, transcriptional regulation, and apoptosis inhibition. CHK1 has emerged as a promising therapeutic target for cancer treatment. To date, over 15 CHK1 inhibitors have advanced into clinical trials, yet none have been approved for marketing.Areas coveredA comprehensive patent review of literature from January 2019 to December 2024 on CHK1 inhibitors in oncology, their combination products, and structural insights have been reviewed through searching relevant information in Scopus, Espacenet, Web of Science, World Intellectual Property Organization, Google Patent databases, Cortellis Drug Discovery Intelligence, and United States Patent and Trademark Office.Expert opinionConsidering the current advancements and the state of the field, the development of potent and selective CHK1 inhibitors with novel skeleton, either as monotherapies or in combination therapies, is of paramount importance. Ongoing research focuses on rational drug design, synergistic treatment integration, and predictive biomarkers identification. These advancements, along with future progress in the realm of CHK1 inhibitors, offer great promise as a pivotal strategy in biomarker-guided cancer therapeutics. |
| WOS关键词 | DOSE-ESCALATION ; LEUKEMIA-CELLS ; KINASE 1 ; PHASE-I ; CHECKPOINT ; DISCOVERY ; CANCER ; REPLICATION ; GEMCITABINE ; COMBINATION |
| 资助项目 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences[CASIMM0120225007] ; National Natural Science Foundation of China[21772174] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001554139900001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321303]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Liu, Tao; Li, Jia |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Zhongshan Inst Drug Discovery, Zhongshan, Guangdong, Peoples R China 4.China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, Nanjing, Peoples R China 5.China Pharmaceut Univ, State Key Lab Nat Med, Nanjing, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Chem Biol, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 7.Zhejiang Univ, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Room 554,Zijingang Campus,866 Yuhang Tang Rd, Hangzhou 310058, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Tao,Su, Mingbo,Wang, Yuxuan,et al. A patent review of CHK1 inhibitors (2019-present)[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2025,35(9):915-931. |
| APA | Liu, Tao.,Su, Mingbo.,Wang, Yuxuan.,Gao, Anhui.,Jiang, Kailong.,...&Li, Jia.(2025).A patent review of CHK1 inhibitors (2019-present).EXPERT OPINION ON THERAPEUTIC PATENTS,35(9),915-931. |
| MLA | Liu, Tao,et al."A patent review of CHK1 inhibitors (2019-present)".EXPERT OPINION ON THERAPEUTIC PATENTS 35.9(2025):915-931. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。